Insight Molecular Diagnostics (IMDX) EPS (Weighted Average and Diluted) (2022 - 2026)

Insight Molecular Diagnostics has disclosed EPS (Weighted Average and Diluted) across 5 years of filings, most recently posting -$0.12 for Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.12, up 53.85% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.5 (up 61.54% YoY), and the FY2025 annual result was -$1.65, up 64.59% from the prior year.
• EPS (Weighted Average and Diluted) came in at -$0.12 for Q1 2026 at Insight Molecular Diagnostics, up from -$0.74 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.64 in Q4 2022 to a low of -$2.3 in Q4 2024.
• The 5-year median for EPS (Weighted Average and Diluted) is -$0.74 (2025), against an average of -$0.67.
• Across the five-year window, EPS (Weighted Average and Diluted) soared 463.64% in 2023 and sank 382.5% in 2024, its largest moves.
• Insight Molecular Diagnostics' EPS (Weighted Average and Diluted) stood at $1.64 in 2022, then tumbled by 205.74% to -$1.73 in 2023, then slumped by 32.62% to -$2.3 in 2024, then surged by 67.83% to -$0.74 in 2025, then soared by 83.78% to -$0.12 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at -$0.12 (Q1 2026), -$0.74 (Q4 2025), and -$0.34 (Q3 2025), per Business Quant data.